United States Liquid Biopsy Market to be Dominated by Multi-Gene Parallel Analysis Technology till 2027
High spending on novel diagnostics technology and
Increased focus on early cancer screening are driving the demand for United
States liquid biopsy Market in the forecast period, 2023-2027.
According to TechSci Research report, “United
States Liquid Biopsy Market By Product & Services (Assay Kits,
Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells,
Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology
(Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR
Microarrays), By Application (Cancer v/s Non-Cancer), By End User (Hospitals
& Clinics, Reference Laboratories, Others), By Region, Competition Forecast
& Opportunities, 2027”, the United States liquid biopsy market is
expected to grow at an impressive rate during the forecast period, 2023-2027.
The adoption of liquid biopsy to tissue biopsy in cancer patients due to its
advanced nature featuring fast turnaround time and feasibility and the ability
to early cancer screening fuel the demand for liquid biopsies in the United
States. The rise in patient preference for non-invasive treatment procedures
and surge in the number of cancer patients are the key driving factors
influencing the United States liquid biopsy market in the forecast period.
However, the lower sensitivity of some liquid biopsies may restrain the
United States liquid biopsy market growth in the forecast period.
Browse over XX
market data Figures spread through 70 Pages
and an in-depth TOC on "United States Liquid Biopsy Market"
https://www.techsciresearch.com/report/united-states-liquid-biopsy-market/8274.html
The United States liquid biopsy market is segmented into product &
services, circulating biomarker, technology, application, end user, regional
distribution, and company.
On the basis of the product & services, the United States liquid
biopsy market is divided into assay kits, instruments, services. Assay kits are
expected to hold the largest market share in the forecast period. The
possibility for repeated sampling for liquid biopsy and the ease and
affordability is driving the demand for assay kits in the forecast period.
On the basis of the circulating biomarker, the United States liquid
biopsy market is divided into circulating tumor cells, circulating tumor DNA
(ctDNA), cell-free DNA (cfDNA), and others. Circulating tumor cells accounted for
the largest revenue share and are expected to maintain their dominance
throughout the forecast period, 2023-2027. The increasing prevalence of cancer
and the advent of ctDNA-based liquid biopsy analysis, which can determine
prognosis tumor progression, is driving the market demand. The detection of
ctDNA, a potential biomarker for cancer, and the growing demand for
non-invasive treatment procedures are bolstering the demand for circulating
tumor cells.
On the basis of the technology, the United States liquid biopsy market
is divided into multi-gene parallel analysis using NGS and single-gene analysis
using PCR microarrays. Multi-gene parallel analysis using NGS technology is
expected to hold the largest market share in the forecast period, 2023-2027. This
technology is highly advanced and can detect several kinds of mutations
responsible for tumors, unknown variants, ctDNA mutation detection, and
resistive mechanism. Rapid advancements in NGS technology to reduce cost and
attain higher accuracy are expected to create lucrative opportunities for the
United States liquid biopsy market in the forecast period.
On the basis of the application, the United States liquid biopsy market
is divided into cancer and non-cancer. Cancer is expected to account for the largest
market share in the forecast period due to the high prevalence of cancer and
high-end investments in research to study the implication of liquid biopsy in
cancer treatment. These are the key factors influencing the market growth in
the forecast period.
On the basis of end user, the United States liquid biopsy market is
divided into hospitals & clinics, reference laboratories, and others.
Reference laboratories are expected to witness significant growth opportunities
in the forecast period. The surge in outsourcing liquid biopsy tests in
reference laboratories due to inadequate infrastructure is driving the demand
for liquid biopsies in reference laboratories.
Download Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=8274
Customers can also
request for 10% free customization on this report.
“The availability of a
well-developed healthcare system, advanced clinical laboratories, and high
demand for advanced instruments and technologies to ease convenience and
effectiveness of treatment is driving the demand for the United States liquid
biopsy market. The surge in demand for tumor treatment and precision diagnosis
and the use of liquid biopsy has opened numerous possibilities for the
effective treatment of cancer which is expected to bolster market growth for
the forecast period. Also, the growing awareness among patients about the
benefits of availing personalized treatment based on drug effect and resistance
and the rise in the allocation of funds by the government to upgrade existing
healthcare infrastructure is expected to propel the United States liquid biopsy
market growth till 2027” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based global management consulting firm.
“United
States Liquid Biopsy Market By Product & Services (Assay Kits, Instruments,
Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor
DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology (Multi-gene Parallel
Analysis using NGS v/s Single-gene Analysis using PCR Microarrays), By
Application (Cancer v/s Non-Cancer), By End User (Hospitals & Clinics,
Reference Laboratories, Others), By Region, Competition Forecast & Opportunities, 2027”,
has evaluated the future growth potential of United States liquid biopsy market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in United States liquid biopsy market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/